本報告已在2011年07月19日停止出版。
美國 10 大生物科技企業，有 186 項產品處於研發階段，其中約 20% 在第 3 層面階段，這些產品預計在 2、3 年後將給市場帶來相當的影響。
專門從事高科技產業顧問及市調服務的美國調查公司 Frost & Sullivan(總公司: 德州)，針對美國 10 家生物科技企業進行風險報酬分析及成本效益分析，並整理出版報告 "Cost Benefit Analysis of Research and Development of Top 10 Biotechnology Companies" 。
本報告書內容包括：生物科技產業總體簡介、美國 10 大生物科技企業資料、研發活動、風險報酬分析及成本效益分析等，內容綱要摘記如下。
1.生物科技產業之簡介
- 生物科技產業之簡介
- 產業結構
- 技術與流程
- 研發流程
- 10 大企業
- 免責事項
- Frost & Sullivan Awards
2.企業分析
- 調查方法
- Amgen Inc.
- Biogen Idec Inc.
- Chiron Corporation
- Genentech, Inc.
- Genzyme Corporation
- Gilead Sciences, Inc.
- InterMune, Inc.
- MedImmune, Inc.
- Millenium Pharmaceuticals, Inc.
- Serono, Inc.
3.產業分析
4.決策支援資料庫（統計資料）
Abstract
Biotechnology Products in Late Stages of Development Promise Market Growth
The top ten biotechnology companies in the United States have 186 products in research and
development (R&D) and of these, nearly 20 percent are in phase III of development. These
products are likely to have substantial impact on market growth in the next two to three years. The
biotechnology industry is optimistic about market growth despite the recent spate of drug recalls in
the pharmaceutical and biotechnology industries, which wiped out billions of dollars of market
capital. Since the fundamentals of product development are sound, the companies are confident of
overcoming these setbacks and accelerating growth.
This Frost & Sullivan research service examines the risk-return and cost-benefit profiles of
research and development of the top ten biotechnology companies in the United States. The study
incorporates a model to evaluate and provide an outlook for each of these companies. It also
analyzes the possible blockbuster products in the product pipelines.
High Returns from Biotechnology Stocks Continue to Drive Investor Interest
The biotechnology market thrives on risk taking. From 1994 to 2005, the top ten companies have
returned an exceptional figure of close to 27 percent on stock price appreciation. In the next year,
this number is expected to reach 24-25 percent, despite a few setbacks in the industry. Established
companies such as Amgen, Chiron, Genentech, and Genzyme are forecast to continue leading the market.
Such high levels of returns from biotechnology stocks are likely to sustain investor interest in the
industry and maintain focus on new R&D projects.
"Biogen IDEC, which has delivered the highest returns of 43.5 percent from 1994 to 2005, has
a risk rating of moderate/high," says the analyst of this research. "Similarly, Gilead
which has returned 29.5 percent, much above the industry average, has the highest risk rating of
very risky."
Licensing Deals and Risk Management Reduces the Perils Associated with Failure
As a drug moves through more advanced stages of R&D, the losses associated with failure are
naturally expected to increase. To counter this situation, biotech companies could enter into
licensing deals and implement risk management solutions. Industry trends point toward an increase in
licensing and partnerships between companies. By sharing the risks and profits, companies can
eliminate or decrease the jeopardy associated with failures.
"The partnerships between big pharma and biotech are likely to be the trendsetters in the
biotech industry," notes the analyst. "With the technical expertise of biotechnology and
the marketing skill of big pharmas, the collaborations are expected to be very successful."
Table of Contents
1 OVERVIEW OF THE BIOTECHNOLOGY INDUSTRY
- Overview of the Biotechnology Industry
- Industry Structure
- Technology and Processes
- Research and Development Process
- Top 10 Companies
- Disclaimer
- Frost & Sullivan Awards
- Best Cost-Benefit Value Award
- Best Risk-Return Value Award
2 COMPANY ANALYSIS
- Methodology
- Risk Return Analysis
- Cost Benefit Analysis
- Amgen Inc.
- Company Profile
- Research and Development
- Risk Return Analysis
- Cost Benefit Analysis
- Biogen Idec Inc.
- Company Profile
- Research and Development
- Risk Return Analysis
- Cost Benefit Analysis
- Chiron Corporation
- Company Profile
- Research and Development
- Risk Return Analysis
- Cost Benefit Analysis
- Genentech, Inc
- Company Profile
- Research and Development
- Risk Return Analysis
- Cost Benefit Analysis
- Genzyme Corporation
- Company Profile
- Research and Development
- Risk Return Analysis
- Cost Benefit Analysis
- Gilead Sciences, Inc
- Company Profile
- Research and Development
- Risk Return Analysis
- Cost Benefit Analysis
- InterMune, Inc
- Company Profile
- Research and Development
- Risk Return Analysis
- Cost Benefit Analysis
- MedImmune, Inc
- Company Profile
- Research and Development
- Risk Return Analysis
- Cost Benefit Analysis
- Millennium Pharmaceuticals, Inc
- Company Profile
- Research and Development
- Risk Return Analysis
- Cost Benefit Analysis
- Serono Inc.
- Company Profile
- Research and Development
- Risk Return Analysis
- Cost Benefit Analysis
3 INDUSTRY ANALYSIS
- Industry Analysis
- Risk Return Analysis
- Cost Benefit Analysis
4 DECISION SUPPORT DATABASES
- Biotechnology & Healthcare
- Biotechnology Companies
- Biotechnology Employees
- Percentage Government Biotechnology Investment
- Biotechnology Patents Granted by USPTO
- Healthcare Expenditure
